Diagnosis of sarcoidosis — the updated ATS 2020 recommendations through the prism of everyday clinical practice by Martusewicz-Boros, Magdalena Maria & Piotrowski, Wojciech Jerzy
EDITORIAL
293www.journals.viamedica.pl




Copyright © 2020 PTChP
ISSN 2451–4934
Magdalena M Martusewicz-Boros, Wojciech J Piotrowski
13rd Lung Diseases and Oncology Department, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland 
2Department of Pneumology and Allergy, Medical University of Lodz, Lodz, Poland
Diagnosis of sarcoidosis — the updated ATS 2020 recommendations 
through the prism of everyday clinical practice
Introduction
Sarcoidosis is a chronic multiorgan granulo-
matous disease of unknown etiology, which most 
often involves the lungs and intrathoracic lymph 
nodes [1]. The latest international guidelines for 
diagnosis and management of the disease were 
published in 1999 [1]. An update of the official 
position of the American Thoracic Society (ATS) 
expert regarding the Clinical Practice Guideline 
for the Diagnosis of Sarcoidosis was released in 
April, this year [2].
The document does not present a signifi-
cantly changed approach to the diagnosis of 
the disease but presents an expert position on 
certain clinical situations that the practitioner 
meets when determining the diagnosis of sarcoid-
osis. The guidelines were developed according 
to the GRADE methodology (Grading of Rec-
ommendations Assessment, Development, and 
Evaluation), based on a systematic review of the 
literature and, where appropriate, meta-analysis, 
in order to summarize the best available evidence. 
Diagnosis of sarcoidosis is not standardized, 
but there is a general consensus that it should 
be based on the following criteria: consistent, 
adequate clinical presentation, demonstration of 
the presence of granulomatous lesions in patho-
morphological examination (in one or more tissue 
samples) and the exclusion of alternative causes 
of granulomatous disease [2].
In this article, the reader will find, briefly 
presented, the most important position of ATS 
experts regarding selected aspects of the diagnosis 
of sarcoidosis, with a comment from the authors 
of this editorial.
Summary of the ATS 2020 recommendations
Pathomorphological examination 
of lymph nodes
In patients who are highly likely to have 
a clinical diagnosis of sarcoidosis (e.g. Lofgren’s 
syndrome, symptoms of “lupus pernio” or Heer-
fordt’s syndrome), a panel of experts allows (sug-
gests) NOT sampling lymph nodes (conditional 
recommendation, very low quality evidence). In 
asymptomatic patients with changes in the ra-
diological image indicating bilateral symmetrical 
pulmonary lymphadenopathy, recommendations 
for or against a lymph node biopsy were not made, 
due to insufficient evidence, either for or against 
a routine lymph node biopsy. The need for further 
close clinical observation is emphasized in all 
patients whose biopsy was postponed. 
In patients with suspected sarcoidosis, with 
hilar/mediastinal lymphadenopathy, in whom 
lymph node sampling is planned, endobronchial 
ultrasound (EBUS) bronchoscopy instead of me-
diastinoscopy is suggested as the first diagnostic 
tool (conditional recommendation, evidence of 
very low quality).
Screening for extrapulmonary sarcoidosis
In all patients diagnosed with sarcoidosis, 
screening for extrapulmonary lesions is suggested. 
Initial ophthalmological examination in all pa-
tients (regardless of the presence of ocular symp-
toms) is suggested as screening for ocular sarcoid-
osis (conditional recommendation, evidence of 
very low quality). 
In the panel of initial laboratory tests, it is 
suggested that   the concentration of serum creat-
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inine for the assessment of kidney involvement is 
determined. Serum alkaline phosphatase should 
be always included in the list of laboratory ex-
aminations as the best marker of liver sarcoidosis 
(experts do not present their opinion for or against 
routine transaminases testing). Complete blood 
cell count as an initial screening for hematologi-
cal abnormalities (conditional recommendations, 
evidence of very low quality) is suggested in all 
patients. The only one strong recommendation in 
the entire document concerns the examination of 
serum calcium levels for abnormal calcium metab-
olism, which is recommended to all patients with 
sarcoid diagnosis (including those who have no 
symptoms or other signs of hypercalcemia) (strong 
recommendation, evidence of very low quality).
If the assessment of vitamin D metabolism is 
considered necessary in a patient with sarcoid-
osis, for instance in patients with indications for 
supplementation therapy, testing of both: 25 and 
1.25-OH vitamin D is suggested (conditional 
recommendation, evidence of very low quality).
To all patients with sarcoidosis who do not 
have cardiac symptoms, a resting electrocardi-
ography (ECG) is recommended as a screening 
test for cardiac involvement (conditional recom-
mendation, evidence of very low quality). If the 
patient has no cardiac symptoms, it is suggested 
that  routine baseline echocardiography (ECHO) 
or outpatient 24-hour Holter ECG monitoring 
(conditional recommendation, evidence of very 
low quality) is NOT performed. The panel of ex-
perts concluded that the final decision whether or 
not to perform ECHO and Holter ECG should be 
considered individually in each case (conditional 
recommendation, evidence of very low quality).
Diagnostics in patients with sarcoidosis 
of suspected extrapulmonary disease
In patients diagnosed with sarcoidosis who 
are suspected of cardiac involvement — cardiac 
magnetic resonance imaging (cMRI) is suggested 
as a test of choice rather than cardiac positron 
emission tomography (cPET) or ECHO to obtain 
both, diagnostic and prognostic information. In 
cases where an MRI examination of the heart is not 
possible (due to lack of access to the equipment 
or contraindications to the procedure), it is sug-
gested that  cPET (conditional recommendations, 
evidence of very low quality) is performed.
To patients diagnosed with sarcoidosis who 
are suspected of having pulmonary hypertension 
(PH), an ECHO test is suggested  (conditional rec-
ommendation, evidence of very low quality). The 
PH suspicion is made up of clinical symptoms, 
including exercise pain in the chest and/or faint-
ing, shortened distance in a 6-minute walk test, 
desaturation during exercise, in addition, results 
of additional tests indicating reduced lung trans-
fer factor for carbon monoxide (TL,CO), enlarged 
pulmonary artery diameter relative to ascending 
aorta diameter assessed in chest computed tomog-
raphy (CT), increased brain natriuretic peptide 
(BNP) and/or the presence of pulmonary fibrosis.
To definitively confirm or exclude PH in 
patients diagnosed with sarcoidosis in whom 
ECHO result is suggestive of PH, right heart cath-
eterization (RHC) is suggested (conditional rec-
ommendation, very low-quality evidence). In the 
absence of suggestive echocardiographic changes 
for PH, individual indications for diagnostic RHC 
should be considered (recommendation based on 
best clinical practice).
Critical remarks and conclusion
The question whether a biopsy is necessary 
in all patients suspected of sarcoidosis has been 
discussed for many years among all experts in 
the field, and this discussion usually results in 
vast spectrum of diverse opinions. Although the 
majority admits that strongly suggestive clinical 
symptoms (i.e. Lofgren syndrome), in addition to 
clear and doubtless radiological signs of bilateral 
lymphadenopathy, firmly support the diagnosis, 
the recommendation does not give a “one-fits-all” 
answer to this question. Erythema nodosum is not 
a specific sign of sarcoidosis, and among a long 
list of potential causes, one can find lymphoma 
and tuberculosis — both possibly presenting 
with mediastinal lymphadenopathy. The value 
of proper evaluation of radiological signs has not 
been stressed in the document strongly enough. 
The recommendation to postpone a biopsy in 
a patient with bilateral hilar lymphadenopathy 
seems to be valid only in individuals with evi-
dently predominant bilateral enlargement of hilar 
lymph nodes, and in case of atypical configuration 
(i.e. predominance of non-hilar lymphadenopathy 
or asymmetry), the decision of a biopsy should 
be sustained. The authors of the guidelines use 
the term “mediastinal lymphadenopathy” not 
assuming an attitude to the presence or absence 
of coexisting parenchymal disease. These axillary 
features may either increase or decrease the di-
agnostic anxiety. Clearly enough, we do not have 
much evidence to answer such a question. EBUS 
is recommended but the question arises whether 
the presence of few epithelioid cells in the cyto-
logical examination indeed allows for exclusion 
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of cancer-related sarcoid-like reaction or lympho-
ma? How to secure the diagnosis of sarcoidosis in 
view of the evidence that many patients suffering 
from tuberculosis and presenting with lymph-
adenopathy show non-caseating granulomas in 
the biopsy? The necessity of close monitoring 
(clearly emphasized by the guidelines’ authors) 
and education of patients about the possible 
symptoms suggestive of alternative and much 
more dangerous diseases, possibly hiding under 
the mask of sarcoidosis, is of special importance. 
To conclude, individual approach is a key issue. 
Doctor’s experience in the field is also extremely 
important, therefore, the best solution is to set 
up reference centers for sarcoidosis in order to 
minimize the risk of improper diagnosis.
The document does not discuss the impor-
tance of biopsies from bronchi or transbronchial 
biopsies (forceps or cryobiopsies). Obtaining 
confirmation of sarcoid granuloma from more 
than one organ significantly increases the prob-
ability of a correct diagnosis. Bronchoalveolar 
lavage (BAL), still routinely used in many centers 
worldwide, and a potential value of flow cytome-
try in the diagnosis of sarcoidosis have not been 
discussed either.
The recommendation concerning screening 
examinations does not cover all routine tests that 
are usually performed in sarcoid patients. There 
are several unanswered questions like the fol-
lowing: are spirometry and TL,CO necessary in all 
patients? Should abdominal ultrasonography be 
performed for screening of abdominal locations 
in all patients? What is the value of chest CT in 
the initial evaluation, and when should it be used 
for monitoring? And last but not least, have we 
forgotten about the assessment of disease activi-
ty? Is it still important? In which patients? What 
about biomarkers (ACE, sR-IL2, neopterin etc.) or 
imaging techniques like PET or scintigraphy? The 
list of unanswered questions is probably much 
longer, and problems may be different depending 
on the local conditions, related to disease pop-
ulation characteristics, health system resources 
and organization.
The authors’ own experience is in line with 
the indication of the cMRI as the superior method 
in assessing the involvement of this organ, after 
confirming sarcoid changes in the pathomorpho-
logical examination of lymph nodes, the lung or 
other organs. MRI allows both morphological and 
functional assessment, providing it is conducted 
according to an adequate protocol. At this point, 
it is worth emphasizing that diagnostic success 
is not dependent on the possibility of performing 
the test, i.e. access to appropriate hardware and 
software, but primarily depends on the substan-
tive preparation of the person who carries out and 
evaluates the test.
In conclusion, the ATS panel of experts 
adopted one strong recommendation regarding 
the evaluation of serum calcemia, 13 condition-
al recommendations and one recommendation 
resulting from clinical practice (“best practice 
statement”). The strength of the recommendation 
regarding the assessment of serum calcemia is 
of great practical importance as significant hy-
percalcemia may be a life-threatening condition. 
Therefore, such assessment should take place in 
every patient at the stage of initial diagnosis, as 
well as in further monitoring of disease course. 
One should always regard a biopsy confirmation 
of sarcoid granuloma as a diagnostic standard, 
considering not only mediastinal lymph nodes 
as a biopsy site but also other techniques like 
bronchial biopsy, transbronchial lung biopsy, and 
other easily accessible locations like peripheral 
lymph nodes. Only in patients with highly sug-
gestive clinical symptoms and typical radiological 
features, the biopsy may be postponed under the 
condition that close monitoring of disease course 
may be secured. The lack of a recommendation 
regarding the necessity of performing lymph 
node biopsies in a patient with asymptomatic 
mediastinal lymphadenopathy reflects the lack 
of sufficiently valuable evidence to support its 
performance in all patients. Regression of changes 
in subsequent imaging exams and a stable radio-
logical image over a 2-year period exempt from 
the obligation of biopsy. In a situation when we 
decide to discontinue a biopsy, it is necessary to 
inform the patient about the need of systematic 
monitoring of the disease course. The patient 
should receive information on the symptoms 
that may indicate the need for deepening and 
reevaluation of the diagnosis. 
The authors agree with the position of ATS 
experts that there is an urgent need for higher 
quality evidence that would support clinical prac-
tice in the diagnosis of sarcoidosis, which would 
help to better understand and define the natural 
course of the disease. Nevertheless, the document 
published by ATS is a valuable proposition of the 
current standard of sarcoidosis diagnosis, based 
on an objective analysis and currently available 
data. Despite having ATS recommendations, 
local societies should undertake an effort of pre-
paring similar documents, asking more detailed 
and specific questions that would consider local 
conditions.
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